HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NSC-741909

antineoplastic; structure in first source

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - NSC-741909: 4

Experts

1.	Fang, Bingliang: 4 articles (01/2011 - 06/2009)
2.	Guo, Wei: 4 articles (01/2011 - 06/2009)
3.	Wang, Li: 4 articles (01/2011 - 06/2009)
4.	Wei, Xiaoli: 4 articles (01/2011 - 06/2009)
5.	Wu, Shuhong: 4 articles (01/2011 - 06/2009)
6.	Wang, Ji: 2 articles (01/2011 - 12/2010)
7.	Liu, Jinsong: 2 articles (04/2010 - 06/2009)
8.	Hollingshead, Melinda: 1 article (01/2011)
9.	Liu, Xiaoying: 1 article (01/2011)
10.	Lu, Zhimin: 1 article (01/2011)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2011 - "In vivo antitumor activity was determined in parallel with NSC-741909 (oncrasin-60) in xenograft tumors established in nude mice from A498, a human renal cancer cell line. " 06/19/2009 - "NSC-741909 is a recently identified novel anticancer agent that suppresses the growth of several NCI-60 cancer cell lines with a unique anticancer spectrum. " 06/19/2009 - "Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells." 12/15/2010 - "NSC-741909 (1-[(4-chlorophenyl)methyl]-1H-Indole-3-methanol) is a novel anticancer agent that is highly active against several NCI-60 cancer cell lines. "
2.	Kidney Neoplasms (Kidney Cancer) 01/01/2011 - "In vivo antitumor activity was determined in parallel with NSC-741909 (oncrasin-60) in xenograft tumors established in nude mice from A498, a human renal cancer cell line. " 04/16/2010 - "NSC-741909 is a novel anticancer agent that can effectively suppress the growth of several cell lines derived from lung, colon, breast, ovarian, and kidney cancers. "
3.	Lung Neoplasms (Lung Cancer) 12/15/2010 - "We tested the combined effects of NSC-741909 and several kinase inhibitors that target the Raf/MEK/ERK1/2 or PI3K/AKT pathways in two sensitive lung cancer cells. "

Related Drugs and Biologics

1.	Antineoplastic Agents (Antineoplastics)
2.	Mitogen-Activated Protein Kinase Kinases (MEKs)
3.	Phosphotransferases (Kinase)
4.	Methanol (Carbinol)
5.	indole